Skip to main content

Table 1 Clinical and biochemical measurements of study participants

From: Impact of blood perilipin A levels on obesity and metabolic health

 

Obese (n = 46)

Non-obese (n = 40)

Total (n = 86)

Mean ± SEM

95% CI

Mean ± SEM

95%CI

Mean ± SEM

95%CI

Range

Age

50.0 ± 1.6

46.9–53.1

40.0 ± 1.7

37.1–43.7

45.5 ± 1.2

43.1.01–48.0

30.0–70.0

Height (cm)

160.4 ± 1.4

157.3–173.2

168.1 ± 1.5

160.8–178.6

164.1 ± 1.2

160.8–175.3

155.7–180.0

Weight (kg)

96.0 ± 1.9*

70.6–152.1

68.2 ± 1.4

51.6–86.3

88.0 ± 3.2

81.6–94.3

50.3–171.2

BMI (kg/m2)

40.47 ± 0.87*

38.72–42.21

22.98 ± 0.41

22.16–23.80

32.4 ± 1.1

30.2–34.5

20.8–52.7

Total Body fat (%)

44.08 ± 1.49*

41.08–47.08

25.50 ± 1.50

22.47–28.53

27.2 ± 2.3

22.5–31.5

5.0–70.0

Visceral fat (%)

18.24 ± 0.86*

16.51–19.97

7.42 ± 1.65

4.08–10.77

13.2 ± 1.1

11.1–15.3

5.0–20.0

Glucose (mmol/L)

5.03 ± 0.07

4.89–5.17

4.97 ± 0.09

4.79–5.15

5.0 ± 0.5

4.8–5.1

3.9–6.1

Total cholesterol (mmol/L)

4.97 ± 0.14

4.68–5.26

4.52 ± 0.12

4.27–4.77

5.42 ± 0.95

4.97–5.96

3.20–8.89

Triglyceride (mmol/L)

1.29 ± 0.07*

1.15–1.44

0.76 ± 0.05

0.67–0.86

1.20 ± 0.49

0.95–1.25

0.34–2.73

HDL-cholesterol (mmol/L)

1.35 ± 0.05*

1.25–1.44

1.65 ± 0.08

1.50–1.80

1.49 ± 0.42

1.40–1.58

0.65–2.84

LDL-cholesterol (mmol/L)

3.03 ± 0.86

2.78–3.29

2.51 ± 0.14

2.24–2.79

2.79 ± 0.96

2.60–2.98

0.79–5.09

VLDL (mmol/L)

0.59 ± 0.03*

0.52–0.67

0.35 ± 0.02

0.31–0.39

0.48 ± 0.24

0.43–0.53

0.16–1.25

Insulin (mlU/ml)

11.84 ± 0.66

10.50–13.17

11.32 ± 0.59

10.10–12.53

11.59 ± 0.37

10.85–12.33

7.23–19.98

HOMA-IR

1.52 ± 0.08*

1.34–1.69

1.437 ± 0.07

1.29–1.58

1.48 ± 0.46

1.40–1.58

0.93–2.47

Perilipin A (pg/ml)

130.8 ± 23.9*

123.7–137.9

159.9 ± 5.2

149.5–170.3

144.3 ± 3.4

97.1–249.0

137.5 –151.1

  1. Data presented as mean ± standard error of the mean (SEM). BMI is body mass index, HDL is high-density lipoprotein, LDL is low-density lipoprotein, VLDL is very low-density lipoprotein, and HOMA-IR is the homeostatic model assessment of insulin resistance.
  2. *p < 0.05 significant (unpaired t-test, two-tailed)